Based on the SIPS model ChangYi proposes marketing strategies for big health brands
According to the “Gen Z Nutrition Consumption Trend Report,” consumers aged 18-35 account for 83.7% of the total health and wellness market, becoming the main force driving growth. Driven by the “Healthy China” initiative and shifting health awareness, the industry is rapidly developing amid fierce competition. Marketing focus has shifte
Yilei Laser Reports Strong Order Backlog and Expands into AI and Humanoid Robotics (June 18, 2025)
At its 2025 performance briefing, Yilei Laser reported a strong order backlog, with a significant portion from large cylindrical full-tab battery assembly lines and overseas market breakthroughs. The company made substantial progress in solid-state battery equipment, perovskite solar, and semiconductor AMHS systems. Yilei is actively expanding into humanoid rob
Next-Gen Automotive Semiconductors Critical for Level 5 Autonomous Vehicles (June 17, 2025)
Michigan engineers lead hardware innovations to enable AI chips required for full Level 5 autonomous driving. Achieving L5 autonomy demands faster, lower-power, and more durable semiconductors. E-Tronic, a leading Chinese automotive power semiconductor supplier, actively participates in next-gen automotive semiconductor development, supporting autonomous vehicl
Pillar Biosciences Raises $34.5 Million to Accelerate Precision Medicine Innovation
In May 2025, Pillar Biosciences announced it had raised $34.5 million in funding, with participation from Illumina, Soleus Capital, and existing investors. The proceeds will be used to expand commercial activities, strengthen partnerships with biopharma companies, and accelerate the adoption of its distributable clinical testing kits worldwide. Pillar’s SLIMa
Unveiled the “Shushan” cryogenic CMOS quantum control chipset (March, 2025)
Unveiled the “Shushan” cryogenic CMOS quantum control chipset, including “Gongga” (superconducting qubit control), “Emei” (qubit readout), and “Xiling” (silicon-based qubit control) chips. “Xiling” was presented at ISSCC 2025, reducing system noise and power consumption for large-scale qubit arrays. Ne
Breakthrough in Quantum Measurement and Control System Technology (March, 2025)
Launched China’s first scalable low-latency feedback quantum control system ZW-QCS560 series, enabling “single-trigger multi-measurement” and rapid feedback control within 300 nanoseconds, solving critical quantum error correction challenges312. News Link : https://finance.sina.com.cn/jjxw/2025-03-05/doc-inenprwv9366586.shtml
Chinese Researchers Achieve Breakthrough in Deep UV Laser Technology (March 26, 2025)
Scientists at the Chinese Academy of Sciences developed a compact solid-state laser system generating a 193 nm coherent vortex beam with improved coherence and reduced power consumption. Using a homemade Yb:YAG crystal amplifier, the system outputs 1030 nm laser light, which is frequency converted through cascaded LBO crystals to produce 193 nm laser with 70 [&
FDA Approves IND for LAE120, a Novel USP1 Inhibitor for Advanced Solid Tumors (March 4, 2025)
In March 2025, Laekna announced that the FDA approved the IND for LAE120, a novel USP1 inhibitor developed internally for advanced solid tumors. LAE120 shows potent monotherapy anti-tumor activity and synergy with PARP inhibitors, especially in homologous recombination deficiency (HRD) cancers. It demonstrated strong tumor inhibition in various xenograft models
E-Tronic Provides Advanced EV Power Electronics Chips Supporting Efficient Battery Management (February 17, 2025)
Chinese startup E-Tronic specializes in power semiconductors and controller systems for the automotive industry. Their vehicle-grade 12V lithium battery management system (BMS) chip supports front-end analog acquisition, power management, intelligent watchdog, CAN/LIN communication, monitoring and diagnosis, high-side drive, and real-time clock. This enables li
Leto Laboratories Developing Semaglutide Biosimilar for Diabetes, Currently in Phase II Clinical Trial (2025)
Leto Laboratories is developing a Semaglutide biosimilar for diabetes and weight loss treatment, currently in Phase II clinical trials. The therapeutic candidate targets the GLP-1 receptor. According to GlobalData, Phase II diabetes drugs have a 38% success rate to advance to Phase III. Leto leverages its high-throughput screening and directional protein refold